- Dr. Neil Kurtz Resigns as President and Chief Executive Officer; Evelyn
Graham Appointed Acting Chief Executive Officer -
LA JOLLA, Calif., Aug. 8 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Neil Kurtz, M.D., is resigning as President, Chief Executive Officer and a director of the company effective as of August 31, 2008. Dr. Kurtz is leaving TorreyPines to assume the role of President and Chief Executive Officer with a major healthcare services company. TorreyPines also named his replacement with the appointment of Evelyn Graham as acting Chief Executive Officer. Ms. Graham has been the company's Chief Operating Officer since 2006.
"We thank Neil for his leadership and many contributions to TorreyPines during his tenure as CEO," said Peter Davis, Ph.D., Chairman of the Board of Directors of TorreyPines.
Dr. Davis continued, "We are proud to announce the appointment of Ev as acting CEO. Her extensive drug development experience and detailed understanding of the company make her the perfect fit to lead TorreyPines as we continue to advance our programs through significant regulatory and clinical milestones."
"I look forward to continuing to work with our current management team in this new role to realize the full potential of our promising product candidates," said Ms. Graham. "We are currently preparing for our end of Phase II meeting with the FDA on September 29th during which we will discuss our proposed Phase III migraine program for tezampanel. In addition, we are continuing to advance NGX426, the oral version of tezampanel, having initiated a Phase I clinical trial to evaluate its analgesic effect. We anticipate announcing results from this Phase I trial by the end of the year, as well as announcing results from an ongoing Phase II clinical trial of our lead muscarinic agonist, NGX267, in xerostomia secondary to Sjogren's Syndrome."
Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005 and Chief Operating Officer in 2006. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in operations management, healthcare utilization and organizational planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A. in biology from the University of Delaware and an M.B.A. from the University of Connecticut.
Second Quarter 2008 Financial Results
The company also reported today its financial results for the second quarter ended June 30, 2008. For the three month period ended June 30, 2008 the company posted revenue of $1.2 million compared to revenue of $2.5 million for the same period in 2007. Operating expenses for the quarter ended June 30, 2008 were $7.2 million, with $5.5 million attributable to research and development. This compares to operating expenses of $8.5 million and research and development expenses of $7.1 million for the same period last year. The net loss for the quarter ended June 30, 2008 was $7.5 million compared to a net loss of $5.2 million for the same period last year. Cash and cash equivalents totaled $20.2 million at June 30, 2008.
Revenue for the six month period ended June 30, 2008 was $3.3 million compared to revenue of $4.9 million for the same period in 2007. Operating expenses for the six month period were $14.0 million, with $10.8 million attributable to research and development. This compares to operating expenses of $15.1 million and research and development expenses of $12.2 million for the same six month period last year. The company reported a net loss for the six months ended June 30, 2008 of $11.3 million compared to a net loss of $8.4 million for the same period last year.
Second Quarter 2008 Accomplishments:
-- Announced that the company will hold an end of Phase II meeting on September 29, 2008 with the U.S. Food and Drug Administration to discuss the tezampanel Phase III development plan for acute migraine.
-- Initiated a Phase I clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of tezampanel. The study will evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli to the skin, induced by intradermal injections of capsaicin. This study, if successful, will allow the company to further benefit from of the versatility of NGX426.
-- Presented data from the tezampanel Phase IIb clinical trial in acute migraine at the American Headache Society's Annual Scientific Meeting. The data showed that in addition to meeting the primary endpoint of headache pain relief at two hours, tezampanel demonstrated improvement on important secondary endpoints including: sustained headache response, absence of nausea, absence of phonophobia and absence of photophobia.
About TorreyPines Therapeutics
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.
Such forward-looking statements include, but are not limited to, statements
regarding the plans for holding an end of Phase II meeting with the FDA,
the potential for tezampanel and NGX426 as treatments for acute migraine
and other indications, the potential for NGX426 to be analgesic, the
anticipated timing of results for the NGX426 study in a model of
capsaicin-induced pain, the potential for NGX267 as a treatment for
xerostomia secondary to Sjogren's syndrome and the anticipated timing of
results from the study of NGX267 as a treatment for xerostomia secondary to
Sjogren's syndrome. Such statements are subject to numerous known and
unknown risks, uncertainties and other factors, which may cause
TorreyPines' actual results to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements, including whether any preclinical studies or clinical trials,
either ongoing or conducted in the future, will prove successful, and if
successful, whether the results can be replicated; whether safety and
efficacy profiles of any of the company's product candidates will be
established, or if established, will remain the same, be better or worse in
future clinical trials, if any; whether pre-clinical results will be
substantiated by ongoing or future clinical trials, if any, or whether any
of the company's product candidates will be able to improve the signs or
symptoms of their respective clinical indication; whether any of the
company's product candidates will support a filing for marketing approval,
will be approved by the regulatory authorities, or if approved, will prove
competitive in the market; or whether the necessary financing to support
the company's product development programs will be available. In particular
there is no guarantee that clinical trials of any of the company's product
candidates will be completed on schedule or that results of these clinical
trials will be reported within the anticipated timeframe, that tezampanel
or NGX426 will successfully treat migraine and/or other indications for
which they are developed, that the End of Phase II meeting will be held in
the anticipated time frame, that NGX267 will successfully treat xerostomia
secondary to Sjogren's syndrome or that TorreyPines will be able to
complete the necessary development work and receive regulatory approval for
tezampanel, NGX426 or NGX267. These and other risks which may cause results
to differ are described in greater detail in the "Risk Factors" section of
TorreyPines' annual report on Form 10-K for the year ended December 31,
2007 and TorreyPines other SEC reports. The forward-looking statements are
based on current information that is likely to change and speak only as of
the date hereof.
Company Contact: Media Contact:
Craig Johnson David Schull
TorreyPines Therapeutics, Inc. Russo Partners, LLC
858-623-5665, x158 212-845-4271
TorreyPines Therapeutics, Inc.
Condensed Consolidated Balance Sheets
June 30, December 31,
Cash and cash equivalents $20,185 $32,500
Prepaid expenses and other current assets 346 835
Total current assets 20,531 33,335
Long-term assets 4,434 5,317
Total assets $24,965 $38,652
Liabilities and stockholders' equity
Current liabilities $5,938 $9,036
Debt and other long-term liabilities 2,823 973
Deferred revenue 450 2,183
Total liabilities 9,211 12,192
Total stockholders' equity 15,754 26,460
Total liabilities and stockholders' equity $24,965 $38,652
TorreyPines Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
License and option
fees $450 $1,700 $1,733 $3,400
Research funding 762 763 1,525 1,525
Total revenue 1,212 2,463 3,258 4,925
development 5,491 7,052 10,751 12,229
administrative 1,751 1,463 3,199 2,858
expenses 7,242 8,515 13,950 15,087
Loss from operations (6,030) (6,052) (10,692) (10,162)
Other income (expense)
Interest income 113 587 330 1,195
Interest expense (110) (216) (257) (453)
(expense), net (1,423) 523 (724) 981
Total other income
(expense) (1,420) 894 (651) 1,723
Net loss $(7,450) $(5,158) $(11,343) $(8,439)
Basic and diluted
net loss per share $(0.47) $(0.33) $(0.72) $(0.54)
shares used in
of basic and
diluted net loss
per share 15,748,104 15,711,588 15,743,875 15,699,834
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved